DARIFENACIN HYDROBROMIDE (darifenacin hydrobromide) by Jubilant Therapeutics is antagonist. Approved for overactive bladder with symptoms of urge urinary incontinence, urgency, frequency. First approved in 2016.
Drug data last refreshed 22h ago
antagonist. Muscarinic receptors play a role in cholinergically mediated functions, including contractions of the urinary bladder smooth muscle. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M 3 receptor than for the other…
Worked on DARIFENACIN HYDROBROMIDE at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.